Loading...
NPI 1528525045 · Sandy Springs, GA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Life Hope Labs LLC is a clinical medical laboratory provider located in Sandy Springs, Georgia. This profile covers 2 Medicare and 3 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Life Hope Labs LLC |
| Address | 5009 Roswell Rd |
| City | Sandy Springs |
| State | GA |
| ZIP | 30342 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | February 21, 2019 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $8.3M |
| Medicaid | $7.3K |
This profile is effectively Medicare-dominant: the provider reports Total Medicare revenue of $8.3M versus Total Medicaid revenue of $7.3K, indicating Medicare accounts for the overwhelming share of billed dollars and that the entity operates as a primarily Medicare-focused lab service on the data shown. Analysts should treat Medicaid activity as de minimis in scale relative to Medicare when evaluating overall financial exposure and payer mix.
Medicare revenue is highly concentrated: the precomputed top 3 Medicare codes by revenue account for 100.0% of this provider's total Medicare revenue, and a single code, K1034, is listed as $8.5M revenue and 100.0% of Medicare revenue. K1034 is reported with 706.7K claims at $12 avg paid/claim and is flagged as an "extreme outlier," so the provider’s Medicare business depends almost entirely on this one COVID-19 OTC/self-test provisioning code.
The provider’s service mix, as reflected in reported codes, indicates an operational focus on COVID-19 testing and distribution rather than traditional clinical diagnostics. K1034 (provision of nonprescription self-administered/self-collected COVID-19 tests) dominates Medicare billing, while Medicaid activity shows both molecular NAAT codes (U0003, U0005) and K1034, implying the lab offers both high-throughput molecular testing and large-scale OTC/self-test provisioning.
Despite the enormous Medicare K1034 volume, the provider is not a broad-based diagnostic outlier across other lab tests: 87481 appears on Medicare with 14 claims, $476 revenue (0.0% of Medicare revenue), and a rank of #1081 of 1117 providers nationally (2nd percentile), which the source characterizes as typical/unremarkable. This suggests the organization’s footprint outside COVID-related codes is minimal in Medicare billing.
Medicaid code billing is also concentrated: the precomputed top 3 Medicaid codes account for 100.0% of this provider's total Medicaid revenue, with U0003 at $4.3K (64.1%), K1034 at $2.1K (31.1%), and U0005 at $324 (4.8%). The Medicaid mix points to a blend of high-throughput molecular testing (U0003/U0005) and continued provision of OTC/self-tests (K1034), though at a very small dollar scale compared with Medicare.
Competitive standing differs sharply by payer and code. For Medicare K1034 the provider ranks #59 of 30143 nationally (100th percentile; extreme outlier), indicating an unusually large national footprint for that specific code; by contrast, Medicaid U0003 ranks #34 of 39 in-state (13th percentile; typical, unremarkable) and U0005 ranks #38 of 41 (8th percentile), while Medicaid K1034 ranks #2 of 5 in-state (75th percentile) — a relatively high position within a very small peer set. Analysts should interpret state-level ranks cautiously because the in-state peer pools for these codes are small.
The provider has a recent but established NPI tenure: enumerated on 2019-02-21 (~7 years ago), suggesting it began operations in the late-2010s and scaled COVID-related services during or after the pandemic period reflected by the dominant codes. This tenure is sufficient to have established operational processes but still relatively recent compared with long-standing laboratory chains.
From a strategic and risk perspective, the entity’s near-total Medicare reliance on K1034 creates concentration risk if reimbursement, demand, or policy for nonprescription/self-test provisioning changes. Given the data-driven dominance of a single COVID-related code on Medicare, payers and analysts should monitor utilization trends, reimbursement policy shifts for K1034, and any changes in mix toward NAAT codes (U0003/U0005) that could materially alter the provider’s revenue profile.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 706,740 | $10 | $8.5M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 10 | $30 | $480 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 2 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 60 | $80 | $4.3K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 2,100 | $1 | $2.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 20 | $20 | $320 |
How this provider's Medicaid billing volume and revenue compare to other Georgia providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Georgia median
3 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 34 | 40 | 850 | $70 | $983K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 38 | 40 | 740 | $20 | $122.4K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 2 | 10 | 890 | $1 | $1.8K |
Other providers in the same ZIP code as Life Hope Labs LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.